Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
193.00
+7.50 (4.04%)
Jul 31, 2025, 1:35 PM CST
4.04%
Market Cap10.82B
Revenue (ttm)26.58M
Net Income (ttm)-379.89M
Shares Out58.35M
EPS (ttm)-6.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume454,305
Average Volume163,014
Open189.00
Previous Close185.50
Day's Range183.50 - 198.00
52-Week Range78.00 - 194.00
Betan/a
RSI83.02
Earnings DateAug 13, 2025

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies. In addition, it engages in the research and development of chimeric antigen rece... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6949
Full Company Profile

Financial Performance

In 2024, Pell Bio-Med Technology's revenue was 19.63 million, an increase of 8.86% compared to the previous year's 18.03 million. Losses were -389.42 million, -2.34% less than in 2023.

Financial Statements

News

There is no news available yet.